核医学用放射性同位元素の世界市場レポート 2025年

核医学用放射性同位元素市場規模は、今後数年間で力強い成長が見込まれます。2029年には124億米ドルに成長し、CAGRは8.5％となります。予測期間の成長は、ヘルスケア支出の増加、ヘルスケアインフラの拡大、環境持続可能性への意識の高まり、教育キャンペーンや意識向上プログラム、医療ツーリズムの成長に起因すると考えられます。予測期間における主な動向としては、新しい放射性同位元素の開発、生産とサプライチェーンの革新、マイクロ流体工学とラボオンチップ技術、放射性医薬品開発における人工知能、ナノテクノロジーなどが挙げられます。

心血管疾患の有病率の増加は、今後数年間における核医学ラジオアイソトープ市場の成長を促進すると予想されます。心血管疾患には、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。これらの疾患の増加は、座りがちなライフスタイル、食生活の乱れ、肥満率の上昇、高齢化などに起因しています。核医学用放射性同位元素は、正確な診断と効果的な治療計画に不可欠な心機能、灌流、組織の生存能力に関する詳細な洞察を提供することにより、心血管疾患の診断、評価、管理に不可欠です。例えば、2024年9月、英国を拠点とする心臓血管研究慈善団体であるBritish Heart Foundationは、英国の約760万人が心臓および循環器疾患に罹患しており、その内訳は男性約400万人、女性約360万人であると報告しました。これらの病気は英国における全死亡の約27％を占め、年間17万人以上、1日あたり約480人、つまり3分に1人が死亡していることになります。その結果、心血管疾患の発生率の上昇が核医学ラジオアイソトープ市場の成長を後押ししています。

核医学用放射性同位元素市場の主なプレーヤーは、放射性同位元素の生産と利用可能性を高めるために、小型低エネルギーサイクロトロンのような革新的な製品の開発に注力しています。小型低エネルギーサイクロトロンは、核医学における医療用画像診断や治療用の放射性同位元素を生成するために使用される小型粒子加速器です。例えば、IBAは2022年1月、診断ソリューションへのアクセスを向上させ、放射性医薬品の内製を可能にするために設計された新しい加速器、サイクロンキーを発表しました。サイクロン・キーは、コンパクトで効率的な設計、完全自動運転、複数のアイソトープ生産能力、設置・操作の容易さ、水冷、自己遮蔽、高性能などの特徴を備えており、汎用性と信頼性に優れています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界核医学用放射性同位元素 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の核医学用放射性同位元素市場：成長率分析
• 世界の核医学用放射性同位元素市場の実績：規模と成長, 2019-2024
• 世界の核医学用放射性同位元素市場の予測：規模と成長, 2024-2029, 2034F
• 世界核医学用放射性同位元素総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の核医学用放射性同位元素市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テクネチウム99m（Tc-99m）
• タリウム201（Tl-201）
• ヨウ素（I-123）
• フッ素18
• ルビジウム82（Rb-82）
• ヨウ素131（I-131）
• ルテチウム177（Lu-177）
• ラジウム223（Ra-223）とアルファラジン
• その他のタイプ
• 世界の核医学用放射性同位元素市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 心臓病学
• 甲状腺
• 神経学
• その他の用途
• 世界の核医学用放射性同位元素市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• 専門クリニック
• 教育調査機関
• その他のエンドユーザー
• 世界の核医学用放射性同位元素市場テクネチウム99m（Tc-99m）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 過テクネチウム酸ナトリウムTc-99m
• Tc-99m MDP（メチレンジホスホネート）
• Tc-99m HMPAO（ヘキサメチルプロピレンアミンオキシム）
• 世界の核医学用放射性同位元素市場タリウム201（Tl-201）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 塩化タリウムTl-201
• 心臓画像診断用タリウム201
• 世界の核医学用放射性同位元素市場ヨウ素123（I-123）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヨウ素123ヨウ化ナトリウム
• ヨウ素123イオフルパン（DaTscan）
• 世界の核医学用放射性同位元素市場フッ素18のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• FDG（フルオロデオキシグルコース）F-18
• 骨画像診断のためのフッ化物18
• 世界の核医学用放射性同位元素市場ルビジウム82（Rb-82）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PET（陽電子放出断層撮影）画像診断用Rb-82
• 心臓画像診断用Rb-82
• 世界の核医学用放射性同位元素市場ヨウ素131（I-131）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• I-131ヨウ化ナトリウム
• 甲状腺がん治療におけるI-131
• 甲状腺機能亢進症治療のためのI-131
• 世界の核医学用放射性同位元素市場ルテチウム177（Lu-177）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• Lu-177-ドタテート
• 前立腺がん治療におけるLu-177
• 世界の核医学用放射性同位元素市場ラジウム223（Ra-223）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• Ra-223二塩化物（ゾフィゴ）
• 世界の核医学用放射性同位元素市場アルファラジン（ラジウム223アルファ線放射体）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 骨転移治療のためのアルファラジン
• 世界の核医学用放射性同位元素市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的アルファ療法（TAT）用 Ac-225
• がん治療のためのAc-225
• ガリウム68（Ga-68）
• 銅64（Cu-64）
• イットリウム90（Y-90）

第7章 地域別・国別分析

• 世界の核医学用放射性同位元素市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の核医学用放射性同位元素市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 核医学用放射性同位元素市場：競合情勢
• 核医学用放射性同位元素市場：企業プロファイル
  • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
  • BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mallinckrodt Pharmaceuticals
• Bracco Imaging S.p.A.
• Lantheus Holdings Inc.
• Curium Pharma
• Australian Nuclear Science and Technology Organisation（ANSTO）Health
• Eckert & Ziegler Strahlen
• NorthStar Medical Radioisotopes
• NTP Radioisotopes
• Shine Medical Technologies Inc.
• Jubilant DraxImage Inc.
• Isotopia Molecular Imaging Ltd.
• EczacIbasI-Monrol Nuclear Products
• International Isotopes Inc.
• Polatom Sp. z o.o.
• Radiomedix Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 核医学用放射性同位元素市場2029：新たな機会を提供する国
• 核医学用放射性同位元素市場2029：新たな機会を提供するセグメント
• 核医学用放射性同位元素市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Radioactive isotopes, known as nuclear medicine radioisotopes, play crucial roles in diagnosing, treating, and researching diverse medical conditions. These isotopes emit radiation that specialized equipment detects and images, aiding in diagnosis, or administer therapeutic radiation doses to specific tissues. Integral to modern medical practices, nuclear medicine radioisotopes offer essential diagnostic information and therapeutic solutions, thereby enhancing patient outcomes.

Among the primary types of nuclear medicine radioisotopes are technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), and others. Technetium-99m (Tc-99m), widely employed in nuclear medicine imaging, facilitates the diagnosis of various medical conditions across oncology, cardiology, thyroid, neurology, and other fields. End users including hospitals, diagnostic centers, specialty clinics, as well as educational and research institutes, benefit from its applications.

The nuclear medicine radioisotopes research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including the nuclear medicine radioisotopes industry's global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.21 billion in 2024 to $8.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. The rise in these diseases can be attributed to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential in diagnosing, assessing, and managing cardiovascular diseases by providing detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnoses and effective treatment planning. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 deaths annually, or approximately 480 deaths per day, which equates to one death every three minutes. As a result, the rising incidence of cardiovascular diseases is fueling the growth of the nuclear medicine radioisotope market.

Key players in the nuclear medicine radioisotopes market are concentrating on developing innovative products such as compact low-energy cyclotrons to enhance the production and availability of radioisotopes, thereby ensuring more efficient and accessible diagnostic and therapeutic options. Compact low-energy cyclotrons are small particle accelerators used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA introduced Cyclone Key, a new accelerator designed to provide increased access to diagnostic solutions and enable in-house production of radiopharmaceuticals. Cyclone Key offers features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.

In April 2024, Telix Pharmaceuticals Limited acquired ARTMS, a Canada-based company specializing in novel radioisotope technology. This acquisition aimed to bolster Telix Pharmaceuticals' nuclear medicine capabilities, optimize production procedures, and expand its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS's innovative radioisotope technology holds promise for advancing nuclear medicine applications and addressing the growing demand for radiopharmaceuticals in the diagnosis and treatment of various medical conditions, including cardiovascular diseases.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
• 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
• 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
• Subsegments:
• 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
• 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
• 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
• 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
• 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
• 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
• 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
• 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)
• 9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment
• 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
• Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Radioisotopes Market Characteristics

3. Nuclear Medicine Radioisotopes Market Trends And Strategies

4. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nuclear Medicine Radioisotopes Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nuclear Medicine Radioisotopes Market Growth Rate Analysis
• 5.4. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM)

6. Nuclear Medicine Radioisotopes Market Segmentation

• 6.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Technetium-99m (Tc-99m)
• Thallium-201 (Tl-201)
• Iodine (I-123)
• Fluorine-18
• Rubidium-82 (Rb-82)
• Iodine-131 (I-131)
• Lutetium-177 (Lu-177)
• Radium-223 (Ra-223) And Alpharadin
• Other Types
• 6.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiology
• Thyroid
• Neurology
• Other Applications
• 6.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Education And Research Institutes
• Other End-Users
• 6.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Pertechnetate Tc-99m
• Tc-99m MDP (Methylene Diphosphonate)
• Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
• 6.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thallous Chloride Tl-201
• Thallium-201 for Cardiac Imaging
• 6.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iodine-123 Sodium Iodide
• Iodine-123 Ioflupane (DaTscan)
• 6.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• FDG (Fluorodeoxyglucose) F-18
• Fluoride-18 For Bone Imaging
• 6.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rb-82 For PET (Positron Emission Tomography) Imaging
• Rb-82 For Cardiac Imaging
• 6.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• I-131 Sodium Iodide
• I-131 For Thyroid Cancer Treatment
• I-131 For Hyperthyroidism Treatment
• 6.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lu-177-DOTATATE
• Lu-177 For Prostate Cancer Treatment
• 6.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ra-223 Dichloride (Xofigo)
• 6.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Alpharadin (Radium-223 Alpha Emitters), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpharadin For Bone Metastasis Treatment
• 6.13. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ac-225 For Targeted Alpha Therapy (TAT)
• Ac-225 For Cancer Treatment
• Gallium-68 (Ga-68)
• Copper-64 (Cu-64)
• Yttrium-90 (Y-90)

7. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

• 7.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Radioisotopes Market

• 8.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Radioisotopes Market

• 9.1. China Nuclear Medicine Radioisotopes Market Overview
• 9.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Radioisotopes Market

• 10.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Radioisotopes Market

• 11.1. Japan Nuclear Medicine Radioisotopes Market Overview
• 11.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Radioisotopes Market

• 12.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Radioisotopes Market

• 13.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Radioisotopes Market

• 14.1. South Korea Nuclear Medicine Radioisotopes Market Overview
• 14.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Radioisotopes Market

• 15.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
• 15.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Radioisotopes Market

• 16.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Radioisotopes Market

• 17.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Radioisotopes Market

• 18.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Radioisotopes Market

• 19.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Radioisotopes Market

• 20.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Radioisotopes Market

• 21.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
• 21.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Radioisotopes Market

• 22.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Radioisotopes Market

• 23.1. North America Nuclear Medicine Radioisotopes Market Overview
• 23.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Radioisotopes Market

• 24.1. USA Nuclear Medicine Radioisotopes Market Overview
• 24.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Radioisotopes Market

• 25.1. Canada Nuclear Medicine Radioisotopes Market Overview
• 25.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Radioisotopes Market

• 26.1. South America Nuclear Medicine Radioisotopes Market Overview
• 26.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Radioisotopes Market

• 27.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Radioisotopes Market

• 28.1. Middle East Nuclear Medicine Radioisotopes Market Overview
• 28.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Radioisotopes Market

• 29.1. Africa Nuclear Medicine Radioisotopes Market Overview
• 29.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

• 30.1. Nuclear Medicine Radioisotopes Market Competitive Landscape
• 30.2. Nuclear Medicine Radioisotopes Market Company Profiles
  • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals
• 31.2. Bracco Imaging S.p.A.
• 31.3. Lantheus Holdings Inc.
• 31.4. Curium Pharma
• 31.5. Australian Nuclear Science and Technology Organisation (ANSTO) Health
• 31.6. Eckert & Ziegler Strahlen
• 31.7. NorthStar Medical Radioisotopes
• 31.8. NTP Radioisotopes
• 31.9. Shine Medical Technologies Inc.
• 31.10. Jubilant DraxImage Inc.
• 31.11. Isotopia Molecular Imaging Ltd.
• 31.12. EczacIbasI-Monrol Nuclear Products
• 31.13. International Isotopes Inc.
• 31.14. Polatom Sp. z o.o.
• 31.15. Radiomedix Inc

32. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

34. Recent Developments In The Nuclear Medicine Radioisotopes Market

35. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

• 35.1 Nuclear Medicine Radioisotopes Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nuclear Medicine Radioisotopes Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nuclear Medicine Radioisotopes Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer